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ABSTRACT
Cancer stem cells (CSCs) are considered to be the root cause for cancer treatment 
failure. Thus, there remains an urgent need for more potent and safer therapies 
against CSCs for curing cancer. In this study, the antitumor activity of cytokine-
induced killer (CIK) cells against putative CSCs of nasopharyngeal carcinoma 
(NPC) was fully evaluated in vitro and in vivo. To visualize putative CSCs in vitro by 
fluorescence imaging, and image and quantify putative CSCs in tumor xenograft-
bearing mice by in vivo bioluminescence imaging, NPC cells were engineered with CSC 
detector vector encoding GFP and luciferase (Luc) under control of Nanog promoter. 
Our study reported in vitro intense tumor-killing activity of CIK cells against putative 
CSCs of NPC, as revealed by percentage analysis of side population cells, tumorsphere 
formation assay and Nanog-promoter-GFP-Luc reporter gene strategy plus time-lapse 
recording. Additionally, time-lapse imaging firstly illustrated that GFP-labeled or 
PKH26-labeled putative CSCs or tumorspheres were usually attacked simultaneously 
by many CIK cells and finally killed by CIK cells, suggesting the necessity of achieving 
sufficient effector-to-target ratios. We firstly confirmed that NKG2D blockade by anti-
NKG2D antibody significantly but partially abrogated CIK cell-mediated cytolysis 
against putative CSCs. More importantly, intravenous infusion of CIK cells significantly 
delayed tumor growth in NOD/SCID mice, accompanied by a remarkable reduction 
in putative CSC number monitored by whole-body bioluminescence imaging. Taken 
together, our findings suggest that CIK cells demonstrate the intense tumor-killing 
activity against putative CSCs of NPC, at least in part, by NKG2D-ligands recognition. 
These results indicate that CIK cell-based therapeutic strategy against CSCs presents 
a promising and safe approach for cancer treatment.
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INTRODUCTION
Nasopharyngeal carcinoma (NPC), one of the most 
common malignant tumors in Southeast Asia [1, 2], often 
invades adjacent regions and metastasizes to regional 
lymph nodes and distant organs, and the great potentiality 
of distant metastases remains the obstacles for survival 
improvement [3]. Novel and effective therapy for NPC is 
urgently warranted.
The development of cancer immunotherapy 
has received considerable attention in the last several 
decades [4–8]. Cytokine-induced killer (CIK) cells have 
demonstrated cancer-killing properties in vitro, killing 
an array of various cancer cell types and anti-tumor 
efficacy in mice and man [4, 7–9]. More importantly, 
CIK cells are capable of migrating to the tumor tissue, 
recognizing the abnormal vasculature and the tumor cells, 
and carrying out subsequent killing of tumor cells [8]. In 
the field of NPC, patients who received autologous CIK 
cell transfusion in combination with gemcitabine plus 
cisplatin chemotherapy had a higher overall survival 
and progression-free survival rates than patients with 
gemcitabine plus cisplatin chemotherapy [10]. However, 
intensive research work will still be required to improve 
CIK cell-based cancer therapy [8, 9].
Cancer stem cells (CSCs)/tumor-initiating cells 
(TICs), which are responsible for tumor initiation, 
maintenance, relapse and metastasis, and therapeutic 
resistance to conventional radio and chemotherapy, are 
considered to be the root cause for cancer treatment failure 
[11–19]. Therefore, there is an urgent need for more potent 
and safer therapies against CSCs for curing cancer.
Immune targeting of CSCs presents a promising and 
safe approach for cancer treatment, and one of the major 
advantages of most immunotherapeutic strategies is low or 
acceptable toxicity [20]. The previous report showed CIK 
cell-based therapy as an enhanced immune cell therapy 
in mice that can target stem-like lymphoma cells [21]. 
Cancer patient-derived CIK cells killed putative CSCs of 
autologous metastatic melanoma [22], and autologous 
metastatic bone sarcoma and soft-tissue sarcomas [23], 
which will be still required to be confirmed by further 
evidence (i.e., tumor sphere formation, time-lapse imaging, 
in vivo experiment, etc) and in various cancers. Additionally, 
so far, the antitumor activity of CIK cells against CSCs of 
NPC is completely unexplored. Against this background, 
in this study, we fully investigated the effects of CIK cell 
treatment on stem cell-like populations in NPC as well as 
the underlying mechanisms by using various methods.
RESULTS
CIK cell treatment resulted in the reduced stem 
cell-like properties of NPC cells
Flow cytometric analysis of CIK cell phenotype was 
illustrated in “Supplemental Results” section and Fig. S1. 
Since our results from “Supplemental Results” section 
showed that CIK cells demonstrated a strong cancer killing 
activity (CKA) in vitro against NPC cells (Fig. 1), we further 
Figure 1: Evaluation of the in vitro cytotoxicity of CIK cells. A. The proliferation ability of CNE2 and SUNE1 cells treated with 
CIK cells were analyzed by CCK8 assay. B. Colony formation assay for CNE2 and SUNE1 cells treated with CIK cells. C. NPC cells 
treated with CIK cells exhibited the reduced motility and invasion. The motility and invasion of CNE2 and SUNE1 cells were analyzed with 
an in vitro migration assay using a transwell chamber and an in vitro invasion assay using a matrigel-coated Boyden chamber, respectively. 
The migrated cells were plotted as the average number of cells per field of view from 3 different experiments, as described in the materials 
and methods section.
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explore the effects of CIK cell treatment on stem cell-like 
populations in NPC.
Side populations (SPs) among NPC cells and 
tumorspheres have been reported to exhibit CSC 
characteristics [24–27]. We first tested the effects of CIK 
cell treatment on the percentages of SP cells in CNE2 
and SUNE1 cells, and found that CIK cell treatment 
dramatically decreased the percentage of SP cells in CNE2 
and SUNE1 cells (Fig. 2A). This data was confirmed on 
several occasions, and found to be statistically significant 
(Fig. 2B). Taken together, our results demonstrate that CIK 
cell treatment can remarkably reduce the cancer stem cell-
like SPs in NPC cells.
We further examined the ability of CNE2 and 
SUNE1 cells to form tumor spheres after treated with 
CIK cells at different E:T ratios by tumorsphere formation 
assay. The results showed that CIK-treated CNE2 and 
SUNE1 cells demonstrated a dramatical decrease in 
tumorsphere formation efficiency in a dose-dependent 
manner (Fig. 2C, 2D). Together, our results indicate 
that CIK cells can efficiently kill cancer stem-like cell 
populations within NPC cell lines in vitro.
Visualization of cancer stem-like cells in NPC 
with a “CSC detector”
The commonly used optical molecular imaging 
techniques include fluorescence and bioluminescence 
imaging [28–30] which have their own advantages. 
Nanog has been frequently used as CSC-related markers 
to identify CSC population from clinical samples and 
cell lines in various cancers, including NPC [31–34]. 
Therefore, based on promoter-reporter gene strategy, 
we have devised and constructed the lentivirus vector of 
pLV-PNanog-GFP-T2A-Luc harboring GFP and luciferase 
(Luc) under control of human Nanog promoter (Fig. 3A), 
which allows us to integrate respective advantages of 
fluorescence and bioluminescence imaging to visualize 
putative CSCs within in vitro cultured cancer cells and 
in vivo optically image and quantify a rare population of 
putative CSCs in human tumor xenograft-bearing mice.
To optically visualize putative CSCs, CNE2 and 
SUNE1 cells were infected with lentiviruses carrying 
PNanog-GFP-T2A-Luc transgene (Fig. 3A). 10 days after 
infection, we found that GFP was highly expressed in a 
small percentage of stably infected CNE2 and SUNE1 
cells (Fig. 3B). Fluorescence activated cell-sorting (FACS) 
analysis revealed the average GFP expression was 5.4% 
in CNE2 cells and 1.4% in SUNE1 cells (Fig. 3C). 
Importantly, the detection of Luc expression showed a 
strong linear correlation (r2 = 0.998) between the total 
CNE2 cell numbers and the bioluminescence signals 
(Fig. 3D, 3E).
Next, GFP-positive (GFP+) and GFP-negative 
(GFP-) cells were sorted, and then gene expression was 
analyzed and the respective assays mentioned below 
were performed (Fig. 3F–3J). Fig. 3F showed that the 
significantly increased levels of the known CSC-related 
Figure 2: CIK cells were active against stem-like cancer cells of NPC. A–B. CIK cell treatment led to the decreased size of SP 
cells. SP cell profiles in the presence of verapamil are shown in the bottom panels. The percentages of SP cells are indicated. Data represent 
the mean ± SD; n = 3. C–D. Images showing tumor sphere formation in CIK-treated NPC cells. Sphere size and density are shown in the 
left panels (C), and the number of spheres is shown in the right panels (D).
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genes (i.e., Nanog, Oct4, Sox2 and Klf4) were observed 
in sorted GFP+ cells, as compared with GFP- cells, 
indicating that GFP+ cells might have stem-cell–like 
characteristics.
CSCs can form tumorspheres in vitro in a non-
attached culture condition [25, 35]. The increased sphere 
forming ability of GFP+ cells was confirmed (Fig. 3G). 
Moreover, approximately 8.3% GFP+ cells (for CNE2) and 
17.5% GFP+ cells (for SUNE1) can form spheres and all 
spheres exhibited GFP expression (Fig. 3G). Additionally, 
colony formation assay showed that GFP+ cells were able 
to induce more colonies than GFP- cells (Fig. 3H). Together, 
GFP+ cancer cells exhibit the characteristics of CSCs.
Furthermore, our data revealed that GFP+ cells 
illustrated a dramatical increase in motile capacity by 
2.7 folds (for CNE2) and 3.8 folds (for SUNE1), and 
a remarkable increase in invasive ability by 4.9 times 
(for CNE2) and 4 times (for SUNE1), compared with 
GFP- cells (Fig. 3I). Epithelial-mesenchymal transition 
(EMT) has been shown to endow cancer cells with 
strong invasive ability. Thus we examined the molecular 
markers of EMT in both GFP+ and GFP- cells by 
Western blot. As expected, GFP+ cells exhibited the 
molecular characterization of mesenchyma with reduced 
expression of E-cadherin and α-catenin, and enhanced 
expression of vimentin and N-cadherin (Fig. 3J). These 
data indicate that the increased migratory and invasive 
capacity of GFP+ cancer cells is coincident with EMT 
phenotype.
Our aforementioned data demonstrate that GFP+ 
cancer cells harboring PNanog-GFP-T2A-Luc transgene 
exhibit the characteristics of CSCs. Therefore, the 
newly established NPC cell lines harboring PNanog-
GFP-T2A-Luc transgene allows us to in vitro visualize 
putative CSCs by fluorescence imaging and in vivo 
optically image and quantify putative CSCs in human 
tumor xenograft-bearing mice by bioluminescence 
imaging.
Figure 3: Visualization of putative CSCs of NPC with a “CSC detector”. A. Schematic diagram of lentiviral vector  
pLV-PNanog-GFP-T2A-Luc, in which GFP and Luc expression was controlled by human Nanog promoter. The construct map is not drawn 
to the scale. Abbreviations: Luc: firefly luciferase; GFP: green fluorescent protein. B–C. Representative GFP expression was measured 
in NPC cell lines (e.g., CNE2 and SUNE1) carrying PNanog-GFP-T2A-Luc transgene by inverted fluorescence microscope (B) and by flow 
cytometry (C). D. CNE2 cells harboring Luc have robust reporter gene expression as shown by bioluminescence imaging (BLI). E. A strong 
correlation exists between BLI signal and CNE2 cell number. F–G. GFP+ and GFP- fractions sorted from CNE2 and SUNE1 cells carrying 
PNanog-GFP-T2A-Luc transgene (shown in Fig. 3B, 3C) by fluorescence-activated cell sorting (FACS) were subjected to Western blotting 
for the detection of Nanog, Oct4, Sox2 and Klf4 expression (F), and tumor spheroid formation assay (G). H–I. The growth (H), migration 
(I) and invasion (I) of GFP+ and GFP- NPC cells were evaluated by colony formation assay, transwell migration assay and matrigel-coated 
Boyden chamber assay, respectively. GFP+ and GFP- fractions were sorted from CNE2 and SUNE1 cells carrying PNanog-GFP-T2A-Luc 
transgene (shown in Fig. 3B, 3C) by FACS. J. GFP+ and GFP- fractions sorted from CNE2 and SUNE1 cells carrying PNanog-GFP-T2A-Luc 
transgene (shown in Fig. 3B, 3C) by FACS were subjected to Western blotting for the detection of E-cadherin, α-catenin, vimentin and 
N-cadherin expression.
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Tumor-killing activity of CIK cells remained 
equally effective against both putative CSCs and 
non-CSCs of NPC
On the basis of GFP expression, NPC cells harboring 
PNanog-GFP-T2A-Luc transgene were sorted into GFP+ and 
GFP- fractions that served as targets to evaluate separately 
the antitumor activity of CIK cells against GFP+ (putative 
CSCs) and GFP- cells. Our results showed that the tumor 
killing activity of CIK cells remained equally effective 
against both GFP+ and GFP- NPC cells (Fig. 4A). In our 
previous study, a stem cell-like subpopulation (PKH26+) 
has been successfully identified in NPC cell lines (e.g., 
CNE2 cells) using a label-retention technique [36]. In 
this study, stem cell-like subpopulation within CNE2 
and SUNE1 cells were labeled by PKH26, as described 
previously [36]. PKH26+ and PKH26- fractions were 
sorted by FACS for subsequent analyses. Our findings 
showed CIK cells can equally efficiently kill both PKH26+ 
and PKH26- cells sorted from PKH26-labelled CNE2 or 
SUNE1 cells (Fig. S2A). Summarily, our data indicate 
that the antitumor activity of CIK cells was equally intense 
against putative CSCs and non-CSCs of NPC.
Time-lapse imaging revealed the direct 
killing effect of CIK cells on stem-like 
cancer cells of NPC
To optically visualize the killing process of CIK cells 
against cancer cells, putative CSCs or tumor spheres, we 
performed time-lapse video recording (Fig. 4B, 4C, 4E, 
and supplemental Movies 1–5). Firstly, we visualized 
the killing process of CIK cells against CNE2 cells by 
time-lapse imaging, and found that one cancer cell was 
generally attacked simultaneously by many CIK cells 
and finally killed by CIK cells (Fig. 4B and supplemental 
Movie 1).
Secondly, we used time-lapse video recording to 
visualize the killing process of CIK cells against putative 
CSCs and non-CSCs of NPC (Fig. 4C, Fig. S2B, S2C and 
supplemental Movies 2–4). As mentioned above, GFP+ 
CNE2 cells harboring PNanog-GFP-T2A-Luc transgene 
exhibit the characteristics of CSCs, and the slow-cycling 
PKH26+ cells within NPC cells are enriched for CSCs 
[36]. Time-lapse video microscopy optically illustrated 
that the tumor killing activity of CIK cells remained 
equally effective against both GFP+ (i.e., putative CSCs) 
and GFP- cells (Fig. 4C, and supplemental Movie 2), and 
both PKH26+ (i.e., putative CSCs) and PKH26- cells 
(Fig. S2B, S2C and supplemental Movies 3–4), indicating 
that the antitumor activity of CIK cells was equally 
intense against putative CSCs and non-CSCs of NPC. 
Furthermore, time-lapse imaging illustrated that each of 
GFP+ or GFP- cells, and PKH26+ or PKH26- cells was 
usually attacked simultaneously by many CIK cells and 
finally killed by CIK cells (supplemental Movies 1–4).
As tumor-derived spheres are highly enriched 
in CSCs [24, 25], we further employed time-lapse 
fluorescence imaging to visualize the killing process of 
CIK cells against tumor sphere of NPC. As shown in 
Fig. 4D, GFP+ tumor sphere was surrounded by many 
red fluorescence-labeled CIK cells when CM-Dil-labeled 
CIK cells were added into culture medium with GFP+ 
tumor spheres. Time-lapse fluorescence video microscopy 
fully revealed that one tumor sphere exhibiting green 
fluorescence from GFP was attacked simultaneously by 
many CIK cells (Fig. 4E and supplemental Movie 5). 
During the process of the continuous attack and killing 
of CIK cells, the GFP+ tumor sphere gradually became 
smaller and it’s shape became irregular, until cancer cells 
within GFP+ tumor sphere were killed completely, while 
green fluorescence emitted from cancer cells became 
more and more weak, until it became nearly or completely 
undetectable at the indicated time range (Fig. 4E and 
supplemental Movie 5). Moreover, complete or near-
complete loss of fluorescence in the most right picture 
of Fig. 4E demonstrated that cancer cells within GFP+ 
tumor sphere in the most left picture of Fig. 4E had been 
scavenged by CIK cells. Furthermore, tumor spheres were 
efficiently scavenged by CIK cells when CIK cells were 
co-cultured with tumor spheres formed from CNE2 cells 
for one day (Fig. 4F). Further in vivo analysis established 
that red fluorescence-labeled CIK cells could infiltrate 
tumors formed from GFP+ cells sorted from CNE2 cells 
harboring PNanog-GFP-T2A-Luc transgene (Fig. 4G). 
Together, these findings strongly suggest that CIK cells 
are active against putative CSCs of NPC.
CIK cells killed stem-like cancer cells of NPC via 
NKG2D-ligands recognition
The MHC-unrestricted tumor-killing activity of 
CIK cells is mainly based on the interaction between their 
membrane receptor NKG2D molecules on CIK cells and 
MIC A/B or ULBPs molecules on tumor cells [9, 37, 38]. 
Our aforementioned results revealed that tumor killing 
activity of CIK cells remained equally effective against 
both putative CSCs and non-CSCs of NPC. Therefore, the 
anti-NKG2D antibody blocking assay was employed to 
define whether CIK cells might kill putative CSCs of NPC 
by NKG2D-ligands recognition.
We first examined the effects of CIK cell treatment 
plus anti-NKG2D neutralizing antibody on the percentages 
of SP cells in CNE2 and SUNE1 cells. We found that after 
CIK cell treatment alone, the size of SP cells in CNE2 
and SUNE1 cells significantly decreased from 4.77 ± 
0.74% and 2.80 ± 0.36% (before CIK cell treatment) to 
1.93 ± 0.78% and 0.77 ± 0.32% (after CIK cell treatment) 
(Fig. 5A), respectively, whereas addition of anti-NKG2D 
antibody mostly rescued the reduced SP cell percentages 
in CIK-treated CNE2 and SUNE1 cells from 1.93 ± 0.78% 
and 0.77 ± 0.32% to 4.17 ± 0.74% and 2.30 ± 0.20% 
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(Fig. 5A), respectively. Together, NKG2D blockade 
mostly restores CIK treatment-induced decrease in the 
percentages of SP cells within NPC cells.
Subsequently, our results showed that addition of 
anti-NKG2D antibody partially but significantly rescued 
CIK treatment-induced decrease in colony formation 
ability (Fig. 5B) and tumor sphere formation ability 
(Fig. 5C) of CIK-treated CNE2 and SUNE1 cells, 
suggesting that NKG2D blockade partially inhibited 
tumor-killing activity of CIK cells.
Finally, we employed GFP+ putative CSCs sorted 
from CNE2 and SUNE1 cells harboring PNanog-GFP-
T2A-Luc transgene to examine whether addition of anti-
NKG2D antibody could block the direct killing effect 
of CIK cells against putative CSCs of NPC by colony 
formation assay and tumor sphere formation assay. 
We observed that addition of anti-NKG2D antibody 
significantly but partially restored CIK treatment-induced 
remarkable reduction in colony formation ability (Fig. 5D) 
and tumor sphere formation ability (Fig. 5E) of CIK-
treated GFP+ putative CSCs of CNE2 and SUNE1 cells, 
indicating that NKG2D blockade partially blocked the 
direct tumor-killing activity of CIK cells against putative 
CSCs of NPC.
All these results certainly indicate that the direct 
tumor-killing effect of CIK cells against putative 
CSCs of NPC, at least in part, by NKG2D-ligands 
recognition.
Figure 4: CIK cells have direct killing effect on stem-like cancer cells of NPC. A. The antitumor activity of CIK cells was 
equally intense against GFP+ and GFP- NPC cells. B. Time-lapse imaging (see supplemental Movie 1) used to observe the interactions 
between CNE2 cells and CIK cells. C. Time-lapse imaging (see supplemental Movie 2) used to observe the interactions between CNE2 cells 
(harboring PNanog-GFP-T2A-Luc transgene) and CIK cells. D. Representative pictures of GFP+ tumor sphere surrounded by CM-Dil-labeled 
CIK cells. GFP+ tumor sphere was generated from GFP+ cells sorted from CNE2 cells harboring PNanog-GFP-T2A-Luc transgene. Red 
fluorescent dye CM-Dil was used to label CIK cells. E. Time-lapse imaging (see supplemental Movie 5) used to observe the interactions 
between GFP+ tumor sphere (derived from GFP+ cells sorted from CNE2 cells harboring PNanog-GFP-T2A-Luc transgene) and CIK cells. 
The explanations of the Figure 4B, 4C, 4E are presented in figure legends of Supplemental Movies. F. CIK cells efficiently killed tumor 
spheres derived from CNE2 cells. Representative pictures of sphere are shown in the left panels, and the number of spheres is shown in the 
right panels. G. Infiltration of PKH26-labeled CIK cells surrounding GFP+ stem-like cancer cells was shown by red fluorescent at frozen 
tissue section. GFP+ cells sorted from CNE2 cells harboring PNanog-GFP-T2A-Luc transgene were subcutaneously injected into the dorsal 
thigh of NOD/SCID mice. After implanted tumor formed, CIK cells labeled with red fluorescent dye PKH26 were injected intravenously 
once a day. 3 days after PKH26-labeled CIK cell implantation, mice were sacrificed, and tumors were dissected, followed by frozen section.
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Pro-inflammatory cytokine secretion by CIK 
cells into co-culture media
Although the non-MHC-restricted tumor-killing 
activity of CIK cells is mainly mediated by the interaction 
of NKG2D with stress-inducible molecules (i.e., MIC A/B 
and ULBPs) on target cells [39–41], the pro-inflammatory 
cytokines secreted by CIK cells also play a role in killing 
cancer cells. Thus we also assessed the cytokine protein 
production by CIK cells. NPC cells were co-cultured with 
CIK cells at an E:T ratio of 30:1 for 24 h, and the co-culture 
supernatants were then harvested and assayed for levels 
of IL-2, IL-4, IL-6, IL-10, TNF-α and IFN-γ by ELISA. 
ELISA showed that CIK cells produced significant amounts 
of IFN-γ and IL-6 (Fig. 6E); whereas slight amounts of 
IL-2, IL-4, IL-10 and TNF-α were produced by CIK cells 
(Fig. 6E), suggesting that compared with IL-2, IL-4, IL-10 
and TNF-α, IFN-γ and IL-6 might play an important role in 
tumor-killing activity of CIK cells against NPC cells.
CIK-treated GFP+ NPC cells exhibited 
significantly increased apoptotic cells
Our findings illustrated that CIK cells efficiently 
killed cancer cells at least by both NKG2D-ligands 
recognition (Fig. 5) and effector cytokines secreted by 
CIK cells (Fig. 6E). Next, TUNEL staining was used to 
detect the apoptosis of putative CSCs and non-CSCs of 
NPC induced by CIK cells. TUNEL staining revealed 
about 16.06 ± 4.71% and 18.11 ± 2.66% of apoptotic 
cells in CNE2 and SUNE1 cells treated with CIK cells 
(Fig. 6A, 6B). Moreover, GFP+ putative CSCs of NPC 
were also treated for 24 h with CIK cells, and subsequently 
TUNEL analysis demonstrated that GFP+ putative CSCs 
showed a markedly high apoptotic rate compared to control 
(Fig. 6C, 6D). Summarily, our studies suggest that CIK 
cells efficiently kill putative CSCs and non-CSCs of NPC 
by inducing apoptosis.
In vivo bioluminescence imaging of tumor-killing 
activity of CIK cells against putative CSCs of 
NPC
Our aforementioned in vitro findings fully revealed 
that CIK cells had a strong ability to attack and efficiently 
kill both putative CSCs and non-CSCs of NPC, as shown 
by various efficient in vitro approaches. We next evaluated 
the tumor-killing activity of CIK cells in vivo against 
putative CSCs of NPC in NOD/SCID mice by in vivo 
optical imaging and other methods.
For in vivo bioluminescence imaging of putative 
CSCs, NOD/SCID mice were subcutaneously implanted 
Figure 5: Blocking of NKG2D with antibody significantly reduced tumor killing activity of CIK cells against putative 
CSCs. A–C. The percentages of SP cells (A), colony formation assay (B) and tumor sphere formation assay (C) in CNE2 and SUNE1 cells 
treated with CIK cells alone and CIK cells which were pre-incubated with anti-NKG2D antibody for 30 min. D–E. Colony formation assay 
(D) and tumor sphere formation assay (E) of GFP+ cells (sorted from CNE2 and SUNE1 cells harboring PNanog-GFP-T2A-Luc transgene) 
treated with CIK cells alone and CIK cells which were pre-incubated with anti-NKG2D antibody for 30 min.
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with the newly established CNE2 cell line harboring 
PNanog-GFP-T2A-Luc transgene. One week after CNE2 
cell implantation, CIK cells were injected intravenously 
into tumor-bearing NOD/SCID mice once every two days 
at doses of 1 × 107 and 3 × 107 cells per mouse, followed 
by the indicated detections and analyses described below. 
Following CIK cell treatment, a significant reduction of 
tumor growth was observed in CIK-treated mice compared 
with untreated controls (Fig. 7A, 7B and Fig. S3), and as 
early as 6 days or 9 days after CIK cell treatment, the 
growth of transplanted tumors between CIK-treated mice 
and untreated controls or between two CIK-treated groups 
became statistically significant (Fig. 7B), respectively.
On day 19, all tumors were excised from NOD/SCID 
mice and weighed, which illustrated the strong anti-tumor 
effects of CIK cells against CNE2 cells (Fig. 7D, 7E), 
followed by histological and immunohistochemical analysis. 
CIK cells that were injected intravenously at doses of 
1 × 107 and 3 × 107 cells per mouse inhibited tumor weight 
by 49% and 74%, respectively (Fig. 7E). Additionally, the 
control and CIK cell-injected NOD/SCID mice exhibited 
body weight gains of 121~128%, and no difference in body 
weight of NOD/SCID mice was found between the CIK–
treated and the control mice, indicating that CIK cell therapy 
did not produce animal toxicity (data not shown). The results 
of immunohistochemical analysis revealed that the number 
of hyperproliferative BrdU- and Ki67-positive tumor cells 
in two CIK-treated groups were significantly decreased 
compared with control (Fig. 7F), while the percentages of 
BrdU- and Ki67-positive tumor cells between two CIK-
treated groups became statistically significant (Fig. 7F).
Furthermore, we also assessed the antitumor activity 
of CIK cells against NPC cells in nude mouse xenograft 
assays (Fig. S4). Our results showed that CIK cell 
treatment inhibited tumor growth of NPC cells in nude 
mice (Fig. S4).
The above-mentioned data from these conventional 
methods fully exhibited that a significant delay in 
the growth of subcutaneous tumor xenografts was 
observed in CIK-treated NOD/SCID and nude mice 
(Fig. 7B, 7D, 7E, 7F and Fig. S4A-S4C). The above-
established subcutaneous tumor xenografts, which 
expressed both GFP and Luc transgenes under the 
control of a stem cell-specific Nanog promoter, allow us 
to in vivo non-invasively optically image and quantify 
putative CSCs within tumor xenografts in NOD/SCID 
mice by noninvasively detecting Luc signal via using 
in vivo bioluminescence imaging. Therefore, when tumor 
sizes of subcutaneous tumors were determined by caliper 
measurement, tumor-bearing NOD/SCID mice were 
imaged at the indicated times by in vivo bioluminescence 
imaging to monitor the changes in the number of putative 
CSCs within tumor xenografts. 
Series of in vivo bioluminescence images taken 
of 3 representative mice from each group are presented 
in Fig. 7A, while quantification of the bioluminescence 
Figure 6: CIK cells efficiently killed NPC cells (including putative CSCs) through the induction of apoptosis and 
secretion of immune cytokines. A–B. CIK-treated CNE2 and SUNE1 cells exhibited significantly increased apoptotic cells detected 
by TUNEL staining. C–D. CIK-treated GFP+ CNE2 and SUNE1 cells showed significantly enhanced apoptotic cells assayed by TUNEL 
staining. After CNE2 and SUNE1 cells (A-B) or GFP+ fractions sorted from CNE2 and SUNE1 cells carrying PNanog-GFP-T2A-Luc 
transgene by FACS (C-D) were co-cultured with CIK cells for 24 h, cancer cells were washed three or four times with PBS to fully remove 
suspended CIK cells, followed by TUNEL staining to detect cells undergoing apoptosis. The FITC-conjugated green signal (A) and Cy3-
conjugated red signal (C) showed the presence of TUNEL-positive cells. DAPI (blue) is used as nuclear counterstain. E. The concentrations 
of IL-2, IL-4, IL-6, IL-10, TNF-α and IFN-γ in 24 h co-culture supernatant were detected by ELISA.
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signal generated from each tumor-bearing mouse is shown 
in Fig. 7C. As shown in Fig. 7A, 7C following CIK cell 
treatment, the significant reduction of bioluminescence 
signal was found in CIK-treated mice compared with 
untreated controls, and as early as 12 days or 17 days post-
treatment of CIK cells, the intensities of bioluminescence 
signal between CIK-treated mice and untreated controls 
or between two CIK-treated groups became statistically 
significant, respectively, indicating that a general 
downward trend in the number of putative CSCs within 
tumor xenografts after CIK cell treatment can be readily, 
noninvasively and optically monitored by in vivo 
bioluminescence imaging.
Since the expression of both GFP and Luc transgenes 
in tumor xenografts is driven by the same Nanog promoter, 
we intended to further quantify number of putative CSCs 
by determining the percentage of GFP-positive cells in 
paraffin-embedded section of tumor xenografts through 
GFP antibody-based staining method. As shown in 
Fig. 7F, GFP antibody-based staining of tumor xenografts 
exhibited that the significant decrease in the percentage 
of GFP-positive cells were found in CIK-treated mice 
compared with untreated controls, and the percentage 
of GFP-positive cells between two CIK-treated groups 
became statistically significant, suggesting a general 
downward trend in the number of putative CSCs within 
tumor xenografts after CIK cell treatment. GFP antibody-
based staining method fully validated the quantification of 
bioluminescence imaging of tumor xenografts. Together, 
these findings from bioluminescence imaging and GFP 
antibody-based staining clearly demonstrate that CIK 
cells treatment leads to the remarkable reduction in the 
number of putative CSCs within tumor xenografts in 
NOD/SCID mice, indicating that CIK cells can efficiently 
Figure 7: In vivo activity of CIK cells against CNE2 cells harboring GFP-T2A-Luc in NOD/SCID mice. As mentioned 
in Materials and methods section, NOD/SCID mice were subcutaneously implanted with 1 × 106 CNE2 cells harboring PNanog-GFP-T2A-
Luc transgene. 7 days after tumor cell implantation, 1 × 107 and 3 × 107 CIK cells were infused by tail vein injection into recipient mice 
once every two days. A. Series of in vivo bioluminescence images (taken at the indicated times) of 3 representative NOD/SCID mice 
from CIK- (1 × 107), CIK- (3 × 107) and vehicle-treated groups before and after CIK cell treatment. B. Growth curve of tumor volumes. 
C. Quantification analysis of bioluminescence signal of tumor-bearing mice treated with CIK cells (1 × 107 and 3 × 107) or with vehicle 
control. D. Representative picture of tumors formed. E. Tumors were weighted. F. BrdU, Ki67 and GFP-stained sections of transplanted 
tumors formed by CNE2 cells at 19 days after subcutaneous transplantation. The percentages of BrdU-, Ki67- or GFP-positive cancer cells 
were calculated by the total number of BrdU-, Ki67- or GFP-positive cells over total number of cancer cells. G. Infiltration of CIK cells at 
tumor sites was shown by immunohistochemistry (Ab anti-CD5 and Ab anti-CD56) at the end of experiment. H. A significant increase in 
transplanted tumor tissue necrosis and apoptosis was observed in CIK-treated mice compared with controls at the end of the experiment.
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kill putative CSCs in vivo, which is likely responsible for 
the significant tumor growth inhibition in mouse xenograft 
model after CIK cell treatment.
Additionally, H&E staining showed that tumors 
from animals treated with CIK cells had significantly 
larger necrotic areas compared to untreated controls 
(Fig. 7H), and CD5 and CD56 immunohistochemistry 
assays confirmed the presence of CIK cells infiltrating the 
tumors formed from CNE2 cells (Fig. 7G).
DISCUSSION
Our currently study reported the in vitro and 
in vivo intense tumor killing activity of CIK cells 
against putative CSCs of NPC, as fully shown by 
various efficient in vitro and in vivo approaches 
described above. Additionally, recent studies reported 
the preclinical antitumor activity of patient-derived CIK 
cells against putative sCSCs of autologous metastatic 
melanoma [22], and autologous metastatic bone 
sarcoma and soft-tissue sarcomas [23], as only revealed 
by in vitro little evidences (i.e., visualizing putative 
CSCs within in vitro cultured cancer cells by Oct4 
promoter-GFP fluorescence reporter gene strategy, and 
tumor killing activity assay of CIK cells towards GFP+ 
putative CSCs), which is still required to be confirmed 
by the above-mentioned methods (i.e., percentage 
analysis of SP cells, tumor sphere formation, time-lapse 
imaging, and in vivo optically imaging and quantifying 
putative CSCs in tumor xenograft-bearing mice, etc). 
Hence, these preliminary findings from our study and 
other investigators [22, 23] illustrate the intense tumor 
killing activity of CIK cells against putative CSCs of 
NPC, melanoma, and bone sarcoma and soft-tissue 
sarcomas. However, intensive research work will still 
be required to be done to explore the intense antitumor 
killing activity of CIK cells towards putative CSCs of 
various other cancers.
The strong cytotoxicity of CIK cells against NPC 
cells, including putative CSCs, prompted us to investigate 
in detail the mechanisms underlying the tumoricidal effect 
of CIK cells towards putative CSCs of NPC. The MHC-
unrestricted anti-tumor activity of CIK cells is mainly 
mediated by the interaction of NKG2D with MICA/B and 
ULBPs[9, 37, 38]. Blocking of NKG2D receptor reduced 
tumor-killing activity of CIK cells against cancer cells of 
bone sarcoma and soft-tissue sarcomas [23]. The antitumor 
activity of CIK cells was equally intense against putative 
CSCs and non-CSCs of NPC (this study), melanoma [22], 
and bone sarcoma and soft-tissue sarcomas [23]. In this 
study, we firstly revealed the direct killing effect of CIK 
cells against putative CSCs of NPC, at least in part, by 
NKG2D-ligands recognition.
MICA/B and ULBPs are the main, but not 
exclusive, ligands recognized by CIK cells; other 
molecules may be implicated [8]. This could explain the 
significant reduction but not abrogation of the cytotoxicity 
of CIK cells observed blocking NKG2D receptor in our 
study (Fig. 5). A more complete definition of all tumor 
ligands recognized by CIK cells, their setting of expression 
and different role in mediating the cytotoxicity of CIK 
cells may help the identification of subsets of cancer 
patients that could better benefit from CIK cell-based 
immunotherapy approaches, suggesting the potential 
clinical relevance deserving dedicated investigations.
In addition, our observations revealed that CIK cells 
secreted significant amounts of IFN-γ and IL-6, and slight 
amounts of IL-2, IL-4, IL-10 and TNF-α, indicating that 
IFN-γ and IL-6 might play an critical role in anti-tumor 
activity of CIK cells against tumor cells, which remains to 
be fully characterized.
Cumulating evidence has revealed that CSCs are 
responsible for tumorigenicity, invasion, metastasis, 
therapeutic resistance and tumor recurrence [42, 43]. 
Thus, the development of methods for in vitro optical 
imaging and non-invasive in vivo detection of putative 
CSCs is of great importance [28, 29]. The commonly used 
optical molecular imaging techniques include fluorescence 
imaging and bioluminescence imaging [28–30] which 
have their own advantages.
At present, the promoter-fluorescence reporter gene 
strategy has been employed to visualize putative CSCs 
within in vitro cultured cancer cells of hepatocellular 
carcinoma [35], melanoma [22], and bone and soft-tissue 
sarcomas [23]. In the aforementioned promoter-reporter 
gene assay, cancer cells harboring GFP gene under control 
of a stem cell-specific Oct4 [22, 23] or Nanog promoter 
[35] were generated to realize visual tracking putative 
CSCs within a population of in vitro cultured cancer cells 
by in vitro fluorescence imaging.
Compared with in vivo fluorescence imaging, 
in vivo bioluminescence imaging possesses high 
spatial resolution and sensitivity and high tissue-
penetration depths, and has frequently been used to 
optically and non-invasively monitor tumor growth, 
regression and metastasis [28–30], suggesting that 
in vivo bioluminescence imaging should provide the 
greatest advantage at in vivo optically imaging, tracking 
and quantifying small numbers of cells (i.e., putative 
CSCs) in human tumor-bearing mice. It is very clear 
that multimodality imaging approaches can minimize 
the potential drawbacks of using each imaging modality 
alone and a tailored combination of two or more 
imaging techniques may be the best approach for a given 
experiment [28–30]. Therefore, we firstly developed a 
new methodology to in vitro and in vivo visualize putative 
CSCs based on a lentiviral “CSC detector” vector encoding 
the copGFP and Luc proteins controlled by human Nanog 
promoter, which has never been reported previously. 
Our data from various experimental methods exhibited 
that GFP+ cancer cells harboring PNanog-GFP-T2A-Luc 
transgene exhibit the characteristics of CSCs. In this study, 
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GFP+ cancer cells (i.e., putative CSCs) were sorted from 
NPC cells carrying PNanog-GFP-T2A-Luc transgene to be 
further used in various experiement mentioned above. 
By time-lapse video recording, the newly established 
NPC cell lines harboring PNanog-GFP-T2A-Luc transgene 
allows us to in vitro visualize the whole killing process 
of CIK cells against GFP+ putative CSCs (Fig. 4), which 
has never been reported previously. More importantly, the 
noninvasive in vivo bioluminescence imaging allowed 
us to readily and optically monitor, for the first time, the 
remarkable reduction in the number of putative CSCs 
within tumor xenografts in NOD/SCID mice after CIK cell 
treatment, which was correlated well with the significant 
decrease in the percentage of GFP-positive cells detected 
by GFP antibody-based staining method. Therefore, the 
NPC cell line harboring double reporter genes (i.e., GFP 
and Luc) under control of a stem cell-specific Nanog 
promoter allows us to in vitro visualize putative CSCs 
and to in vivo optically image and quantify putative CSCs 
within tumor xenograft-bearing mice, which has never 
been reported in other cancers.
As mentioned above, real-time imaging of the 
interactions between CIK cells and NPC cells greatly 
helps us to understand the killing process of CIK cells 
against cancer cells, including putative CSCs or tumor 
spheres. In this study, time-lapse video microscopy fully 
revealed that when CIK cells were in vitro co-cultured 
with them, each of cancer cells, GFP-labeled or PKH26-
labeled putative CSCs, or tumor spheres was usually 
attacked simultaneously by many CIK cells and finally 
killed by CIK cells, suggesting that it is quite necessary to 
achieve sufficient effector to target ratios if cancer cells, 
including putative CSCs and tumor spheres, are expected 
to be efficiently killed by CIK cells in vitro and in vivo. 
Collectively, our current study firstly revealed the killing 
whole process of CIK cells against putative CSCs or tumor 
spheres by time-lapse video microscopy.
As shown above, CSCs/TICs are the root cause for 
the cancer treatment failure, however, the development 
of new therapeutic strategies targeting CSCs is currently 
hindered by the lack of reliable markers for the 
identification of these CSCs [11–19]. Moreover, one of 
the key goals in cancer research over the past decade has 
been to develop therapeutic strategies to efficiently and 
safely eliminate CSC population for curing the cancer 
with no or minimal damage to the normal tissues, but a 
major hurdle to this goal lies in the identification of the 
key mechanisms that distinguish CSCs from the normal 
endogenous tissue stem cells [11–19]. One of the major 
advantages of most immunotherapeutic strategies 
(e.g., CIK cell-based anticancer immunotherapy) is 
relatively low or acceptable toxicity against the normal 
tissues and cells, in contrast to traditional chemotherapy 
and radiotherapy, whereas the findings from this study and 
other investigators [8,20,22,23,44] showed that CIK cell-
based immunotherapy for cancer exhibited a high cytotoxic 
activity against cancer cells, including CSCs. Therefore, 
CIK cell-based therapeutic strategies against CSCs presents 
a promising and safely approach for cancer treatment.
Although CIK cell therapy for cancer patients 
exhibits the attractive advantages over other adoptive 
immunotherapies, evidence supporting the need for 
therapy-enhancing strategies has come from clinical trials 
conducted using CIK cell therapy alone. Several strategies 
have been adopted to enhance CIK cell function and 
improve the anti-tumor efficacy of CIK cells [45]. These 
strategies include the use of chimeric antigen receptors 
(CARs) [46–51] and bispecific antibodies (BsAb) [52–56] 
to re-direct CIK cells toward specific cancer targets. CAR 
based immunotherapy has been under development for 
the last 25 years and is now a promising new treatment 
modality in the field of cancer immunotherapy and 
clinical studies of this approach have shown a promising 
anti-tumor activity [5]. CAR-engineered CIK cells resulted 
in more efficient tumour cell lysis [8, 46–51]. Moreover, 
EGFRvIII CAR-engineered T cells exhibited a strong 
antitumor activity against glioma stem cells expressing 
mutant EGFRvIII, but not wild-type EGFR [57], while it is 
necessary to explore whether CAR-engineered CIK cells 
more efficiently killed stem-like cancer cells of various 
cancers, compared with CIK cells alone.
The advantages of CIK cell therapy over other types 
of autologous T cell therapies including CAR T cells are 
the effective tumor homing abilities and recognition of 
stress ligands, not tumor-specific antigens, for tumor cell 
killing [8]. These extend the therapeutic value to numerous 
types of cancer including solid tumors. Applying CARs 
to CIK cells improves specific tumor killing, but will 
still not overcome the effector to target ratio problem [8], 
indicating that there is an urgent need for the approaches 
to achieving sufficient effector to target ratios.
The previous studies revealed that CIK cell 
delivery of the vaccinia virus directly to the tumor can 
help overcome the localized tumor immunosuppressive 
environment and increase subsequent immune cell 
infiltrates to achieve sufficient effector to target ratios [58, 
59], suggesting that CAR-engineered CIK cell delivery 
of the oncolytic virus directly to the tumor may attain 
sufficient effector to target ratios, which remains to be 
confirmed. This strategy considers the tumor homing 
and recognition capabilities of CIK cells along with the 
constraint of achieving sufficient effector to target ratios.
Other alternatives include co-culturing CIK 
cells with dendritic cells (DC) to improve activation, 
enhancement with coadministration of synergistic drugs 
and cytokines, but these methods increased the complexity 
of enrichment without providing a dramatic increase in 
anti-tumor efficacy [8].
In summary, our in vitro and in vivo findings here 
demonstrate the intense tumor killing activity of CIK cells 
against putative CSCs of NPC, indicating that immune 
targeting of CSCs presents a promising approach for 
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safe cancer treatment. These data prompt us to further 
investigate the antitumor activity of NPC patient-derived 
CIK cells against autologous NPC cells, including putative 
CSCs. On the other hand, as immunotherapy often 
needs to be accompanied by other therapeutic strategies 
(e.g., chemotherapy and/or radiotherapy), we will carry 
out further preclinical and clinical investigations on the 
prospective potential of targeting putative CSCs of NPC 
with CIK cells in synergism with traditional treatment 
strategies such as radiotherapy. CIK cell-based anticancer 
immunotherapy is becoming a fascinating tool in the 
fight against cancer, and its further development in the 
near future is guaranteed. CIK cell-based anticancer 
immunotherapy could be a very promising adjunct to 
traditional cancer treatments.
MATERIALS AND METHODS
Cell lines and cell culture
Human NPC cell lines (i.e., CNE2 and SUNE1 cells) 
were obtained from Prof. Qiao Tao (Chinese University of 
Hong Kong, Hong Kong, China). These NPC cell lines 
were cultured in RPMI 1640 medium supplemented with 
10% fetal bovine serum (FBS) in a humidified incubator 
with 5% CO2 at 37°C. HEK293T cells were maintained 
in DMEM medium supplemented with 10% fetal bovine 
serum (FBS; Biological Industries), 1 mM glutamine and 
1% nonessential amino acids in a humidified incubator 
with 5% CO2 at 37°C.
Ex vivo generation, expansion and phenotype 
analysis of CIK cells
Human peripheral blood samples were obtained 
from healthy volunteer blood donors. All individuals 
provided their informed consent. Human peripheral 
blood mononuclear cells (PBMCs) were separated 
from heparinized peripheral blood by Ficoll–Hypaque 
density gradient centrifugation, and then washed 
twice with PBS. Next, PBMCs were re-suspended at 
1 × 106 cells/mL in RPMI 1640 (Corning) containing 10% 
FBS, and cultured in the presence of anti-CD3 antibody 
(500 ng/mL, Miltenyi, Germany), IFN-γ (100 U/mL, 
Shanghai Kaimao, China), Polyhydroxyalkanoates (PHA)
(10 µg/mL, Huizhou Hongyu, China) and recombinant 
human interleukin-2 (IL-2)(1000 U/mL, Beijing Sihuan, 
China) in culture flask for two days. Following this, Fresh 
medium containing IL-2 and anti-CD3 antibody was 
replenished every two or three days during culture. Cells 
were expanded over 3 weeks of time period. Phenotypes of 
CIK cells were weekly analyzed with a FACSCalibur flow 
cytometry (BD Biosciences). The following monoclonal 
antibodies (mAb) were used: CD3-FITC, CD4-FITC, 
CD8-PE, CD56-APC and CD314-APC (anti-NKG2D) 
(Miltenyi, Germany).
CCK8 assay and colony formation assay
Tumor-killing activity of CIK cells against NPC 
cells was assessed by CCK8 assay. Briefly, CNE2 
and SUNE1 cells were plated in 96-well plates at 
5 × 103 cells/well, and then CIK cells were added to 
96-well plates at specified effector: target ratios (5:1, 
10:1, 30:1 and 50:1) in a final volume of 200 μL and 
co-cultured with NPC cells for 6 h. Tumor cells alone and 
CIK cells alone were used as the target cells alone group 
(blank control group) and the effector cells alone 
group, respectively. The inhibition rate was calculated 
according to the following formula: inhibition rate 
(100%) = [1- (A value in experimental well - A value in 
effector cell wells)/A value in target cell wells] × 100%.
After NPC cells were co-cultured with CIK cells at 
specified effector: target ratios (5:1, 10:1, 30:1 and 50:1) 
for 24 h, NPC cells were washed three or four times with 
PBS to fully remove the suspended CIK cells, and then 
used for colony formation assay. Colony formation assay 
was previously fully described [36].
Transwell migration assay and Boyden 
invasion assay
After NPC cells were co-cultured with CIK cells at 
specified effector:target ratio (10:1) for 24 h, NPC cells 
were washed three or four times with PBS to fully remove 
the suspended CIK cells, and subsequently collected 
and counted for transwell migration assay and Boyden 
invasion assay, as described previously [60].
Percentages of side population cells (SP cells) 
analyzed by flow cytometry
CNE2 and SUNE1 cells were firstly co-cultured 
with CIK cells for 24 h, and then NPC cells were washed 
three or four times with PBS to remove the suspended 
CIK cells. Next, NPC cells treated with CIK cells were 
digested with 0.25% trypsin, washed twice with calcium/
magnesium-free PBS, resuspended in ice-cold RPMI-1640 
medium (supplemented with 2% FBS) at a concentration 
of 1 × 106 cells/mL, and incubated at 37°C in a 5% CO2 
incubator for 90 min. Following this, the changes in the 
percentage of SP cells were analyzed by flow cytometry 
(BD FACSAria), as previously fully described [25].
Tumor spheroid formation assay
After NPC cells were co-cultured for 24 h with CIK 
cells at different effector: target ratios, NPC cells were 
washed three or four times with PBS to fully remove 
the suspended CIK cells, and subsequently cancer cells 
were collected and counted for tumor spheroid formation 
assay. Next, 9000 cells were plated in 6-well ultralow 
attachment plates (Corning, Corning, NY) in serum-free 
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DMEM-F12 (Hyclone), supplemented with 20 ng/mL 
epidermal growth factor (Peprotech), 10 ng/mL basic 
fibroblast growth factor (Peprotech), and B27 supplement 
(1:50 dilution; BD). After 7 days of culture, the number of 
tumor spheres was counted under an inverted microscope.
Plasmids and lentivirus vector construction
The plasmid of pL-SIN-PNanog-EGFP, carrying 
human Nanog promoter, was obtained from Addgene 
(plasmid 21321). The lentivirus vector of pOct4CR4-
pGreenFire1™ EF1-Puro (SR20070-PA-P) was purchased 
from System Biosciences (SBI). The lentiviral packaging 
plasmids psPAX2 and pMD2.G were kindly provided 
by Prof. Didier Trono (University of Geneva, Geneva, 
Switzerland).
Human Nanog promoter fragment were amplified 
from pL-SIN-PNanog-EGFP, and then directly inserted into 
EcoR I and BamH I sites of pOct4CR4-pGreenFire1™ 
EF1-Puro to generate pLV-PNanog-GFP-T2A-Luc. This 
complete sequence of human Nanog promoter fragment 
was confirmed through DNA sequencing. Thus, the 
resultant plasmid of pLV-PNanog-GFP-T2A-Luc harbors 
both the reporter genes [i.e., GFP and luciferase (Luc)] 
under control of Nanog promoter and puromycin 
resistance gene under control of EF-1α promoter.
Lentivirus production and transduction
To generate stable cell lines, recombinant 
lentiviruses (named as LV-PNanog-GFP-T2A-Luc) were 
generated as previously described [61], and subsequently 
used to infect CNE2 and SUNE1 cells. Next, stable 
infected cells were selected with puromycin in 4 μg/ml 
concentration to establish puromycin-resistant stable 
reporter cell lines (i.e., CNE2 and SUNE1 cells) carrying 
PNanog-GFP-T2A-Luc transgene, followed by GFP assay 
via inverted fluorescence microscope (Nikon, Japan) and 
flow cytomety (BD FACSAria). Moreover, GFP+ and 
GFP- fractions were sorted for subsequent experiments 
by fluorescence-activated cell sorting (FACS) (BD 
FACSAria).
Western blot analysis
Protein lysates were separated by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), and transferred to a polyvinylidene difluoride 
(PVDF) membrane. The blots were probed with 
the indicated primary antibodies, followed by HRP 
(horseradish peroxidase)-labeled secondary antibodies. 
The hybridization signal was detected using enhanced 
chemiluminescence (ECL) (Cat.No:KGP1122, KeyGEN 
BioTECH). GAPDH was used as a loading control. The 
antibodies used in this study were shown in Table S1.
PKH26 labeling of cancer cells and sorting of cell 
populations
CNE2 and SUNE1 cells were labeled using PKH26 
Red Fluorescent Cell Linker Kit (Sigma-Aldrich) before 
cell culture, as described previously [36]. Labeled CNE2 
and SUNE1 cells were cultured for about 3–4 weeks. 
PKH26+ and PKH26- fractions were sorted for subsequent 
tumor-killing activity assay and time-lapse imaging 
by fluorescence-activated cell sorting (FACS) (BD 
FACSAria).
PKH26 and CM-Dil labeling of CIK cells
In some experiments of this study, to distinguish the 
CIK cells from GFP-labeled tumor cells, red fluorescent 
dyes, including PKH26 (Sigma-Aldrich) and CM-Dil 
(Sigma-Aldrich), were used to label CIK cells, according 
to the instructions provided by the manufacturer.
Time-lapse imaging
To observe the interactions between cancer cells or 
tumor spheres and CIK cells, time-lapse recording was 
performed using an in-incubator microscope (LumaScope 
model 600, Etaluma, USA). Image acquisition was begun 
immediately after CIK cells were added into culture dish. 
Images were captured every 2 min for 12 h (cells) or 4 min 
for 24 h (tumor spheres). These images were processed 
using the LumaView 600 software (Etaluma, USA).
Anti-NKG2D antibody blocking assay
To investigate the mechanisms underlying the 
tumoricidal effect of CIK cells, CIK cells were firstly 
pre-incubated for 30 minutes with 20 μg/mL of inhibitory 
anti-NKG2D neutralizing antibody (Clone #552866, BD 
Pharmingen), and subsequently co-cultured with NPC 
cells for 24 hours, followed by SP cell percentage analysis, 
colony formation assay and tumor spheroid assay.
TUNEL staining
After CNE2 and SUNE1 cells were treated with 
CIK cells for 24 hours, NPC cells were washed three or 
four times with PBS to fully remove suspended CIK cells, 
dried at room temperature, fixed with 4% formalin for 
15 minutes, and then underwent TUNEL staining by using 
the TUNEL Apoptosis Detection Kit (KeyGEN BioTECH) 
according to the manufacturer’s instruction.
Cytokine detection by ELISA
After NPC cells were treated with CIK cells for 
24 hours, cell culture supernatants were collected by 
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centrifuging at 2000 × g for 10 min at 4°C and stored 
at -80°C before use. The cytokine levels in the collected 
 co-culture supernatants were determined by ELISA kit (for 
IL-2, IL-4, IL-6, IL-10, TNF-α and IFN-γ) (MultiSciences, 
China) according to the manufacturer’s instructions.
Xenograft experiments in NOD/SCID mice
The animal experiments were carried out in strict 
accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the 
Southern Medical University. The animal protocol 
was approved by the Committee on Ethics of Animal 
Experiments of the Southern Medical University. 
NOD/SCID mice were purchased from the Model 
Animal Research Center of Nanjing University, and 
housed in microisolator cages under aseptic conditions. 
CNE2 cells (1 × 106 cells) harboring PNanog-GFP-T2A-
Luc transgene were resuspended in a mix of PBS 
and BD Matrigel (BD Biosciences) (1:1), and then 
subcutaneously injected into the right or left dorsal 
thigh of mice. 1 week after CNE2 cell implantation, 
the mice were treated with 1 × 107 CIK cells, 
3 × 107 CIK cells or PBS as the untreated control 
via tail vein injection once every two days. Tumor 
growth was determined by caliper measurement or 
in vivo bioluminescence (BLI) (see below). Tumor 
volumes were calculated as previously described [62]. 
On day 19 after cancer cell implantation, mice were 
sacrificed, and tumors were dissected, weighed and 
fixed overnight in 4% paraformaldehyde, dehydrated, 
paraffin-embedded, sectioned. All surgery was 
performed under sodium pentobarbital anesthesia, and 
all efforts were made to minimize suffering of animals.
In vivo bioluminescence imaging
The protocols for whole-animal bioluminescence 
imaging to noninvasively detect the activity of Luc by 
the Xenogen IVIS Lumina II Imaging System (Xenogen 
Corp., Alameda, CA, USA) were previously well 
described [63, 64].
Histological and immunohistological 
examinations
For histology analysis, tumor tissues were fixed 
with 4% paraformaldehyde (PFA) in PBS, embedded 
in paraffin, cut into 5 μm thick sections, and then 
deparaffinized, followed by hematoxylin and eosin 
staining (H&E staining) according to standard procedures. 
After deparaffinization and rehydration, the paraffin-
embedded sections were subjected to high pressure for 
2 min for antigenic retrieval. The slides were incubated 
overnight at 4°C with the indicated primary antibodies 
(Table S2).
Statistical analysis
Data were presented as mean ± SD. Statistical 
analysis was performed using a SPSS 13.0 software 
package and Graphpad 5.0 software. Independent-Sample 
T test was used for comparisons of 2 independent groups. 
The One-Way ANOVA was used for compare comparisons 
of multiple groups. The mixed model analysis of variance 
(Two-Way ANOVA) was employed to assess CIK 
cytotoxic activity curves in vivo. Statistical significance 
was assessed by the Student’s t-test (* or #P < 0.05; **or 
##P < 0.01).
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